Treatment of central nervous system disorders
Devices and methods for treating central nervous system disorders by administering light to a user are disclosed. In some embodiments, the devices are positioned away from the user, and in other embodiments, the devices are attached to the user. In some embodiments, the light is applied through the users skin, and in other embodiments, through an implanted or percutaneous device. Representative central nervous system disorders include cognitive, motor, and behavioral disorders. Where these disorders include an inflammatory component, light is administered at wavelengths which decrease inflammation in the brain. Where these disorders are caused by poor vascularization, light is administered at wavelengths which improve vascularization in the brain. The methods also include repairing damage to the blood brain barrier, and can be used to more effectively administer drugs, such as anticancer drugs, to the brain.
1 . A method for treating central nervous system disorders, comprising administering light to a patient in need of treatment thereof, wherein the light comprises a first wavelength that reduces inflammation in the brain, and a second wavelength that increases vascularization in the brain, and wherein the light is administered in a manner that repairs damage to the blood brain barrier by positioning one or more light sources that generate the first wavelength and the second wavelength at a spaced distance from a scalp of the patient and administering the light to penetrate the scalp.
2 . The method of claim 1 , wherein the spaced distance is within 100 centimeters of the scalp.
3 . The method of claim 1 , wherein the central nervous system disorders are cognitive disorders, motor disorders, or behavioral disorders.
4 . The method of claim 3 , wherein the cognitive disorders are selected from the group consisting of Alzheimer's disease, amnesia, Binswanger's disease, cerebellar cognitive affective syndrome, clinical dementia rating, clouding of consciousness, cognitive deficit, cognitive slippage, cognitive vulnerability, corticobasal degeneration, corticobasal syndrome, delirium, dementia, disabilities affecting intellectual abilities, frontal assessment Battery, frontotemporal dementia, frontotemporal dementia and parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, HIV-associated neurocognitive disorders, learning problems in childhood cancer, Lewy body dementia association, Lewy body dementia, logopenic progressive aphasia, mild cognitive impairment, paratonia, Pick's disease, post-chemotherapy cognitive impairment, postoperative cognitive dysfunction, primary progressive aphasia, progressive nonfluent aphasia, progressive supranuclear palsy, pseudosenility, REM sleep behavior disorder, semantic dementia, severe cognitive impairment, subcortical dementia, and vascular dementia.
5 . The method of claim 3 , wherein the cognitive disorders are selected from the group consisting of Alzheimer's disease, dementia, and mild cognitive impairment.
6 . The method of claim 3 , wherein the motor disorders are selected from the group consisting of hypokinetic movement disorders, Parkinson's disease (Primary or Idiopathic Parkinsonism), secondary Parkinsonism, Parkinson plus syndromes, Hallevorden-Spatz Disease, progressive supranuclear ophthalmoplegia, striatonigral degeneration, hyperkinetic movement disorders, dystonia, including drug-induced dystonia, idiopathic familial dystonia, idiopathic non-familial dystonia, idiopathic orofacial dystonia, spasmodic torticollis, blepharospasm, and other dystonias, extrapyramidal movement disorders, essential tremors, drug induced tremors, myoclonus, opsoclonus, chorea (rapid, involuntary movement), including drug-induced chorea, rheumatic chorea (Sydenham's chorea), and Huntington's Chorea, ballismus (violent involuntary rapid and irregular movements), hemiballismus (affecting only one side of the body), athetosis (contorted torsion or twisting), dyskinesia (abnormal, involuntary movement), tardive dyskinesia, tic disorders (involuntary, compulsive, repetitive, stereotyped), including Tourette's syndrome and drug-induced tics and tics of organic origin, stereotypic movement disorder, paroxysmal nocturnal limb movement, painful legs (or arms), moving toes (or fingers) syndrome, sporadic restless leg syndrome, familial restless leg syndrome, stiff-person syndrome, abnormal head movements, cramp and spasm, and fasciculation.
7 . The method of claim 3 , wherein the motor disorders are selected from the group consisting of Parkinson's disease and tardive dyskinesia.
8 . The method of claim 3 , wherein the behavioral disorders are selected from the group consisting of attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorders, schizophrenia, generalized anxiety disorder, specific phobia, social anxiety disorder, separation anxiety disorder, agoraphobia, panic disorder, selective mutism, major depressive disorder, catatonic depression, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), dysthymia, double depression, depressive personality disorder (DPD), recurrent brief depression (RBD), minor depressive disorder (minor depression), depressive disorder not otherwise specified (DD-NOS), and bipolar disorders.
9 . The method of claim 3 , wherein the behavioral disorders are selected from the group consisting of depression, anxiety, schizophrenia, seasonal affective disorder (SAD), and attention-deficit hyperactivity disorder (ADHD).
10 . The method of claim 3 , further comprising administering one or more drugs useful for treating cognitive disorders.
11 . The method of claim 3 , further comprising administering one or more drugs useful for treating motor disorders.
12 . The method of claim 3 , further comprising administering one or more drugs useful for treating behavioral disorders.
13 . The method of claim 1 , wherein the first wavelength that reduces inflammation is between 640 nm and 680 nm.
14 . The method of claim 1 , wherein the second wavelength that increases vascularization is in a range of from 400 nm to 490 nm.
15 . The method of claim 1 , wherein the light is administered using a device which delivers light to the scalp.
16 . The method of claim 1 , wherein the light is administered using a device which delivers light to the nose.
17 . The method of claim 1 , wherein the light is administered using a device which delivers light to the eyes.
18 . The method of claim 1 , wherein the light is administered using a device which delivers light to the ears.
19 . The method of claim 1 , wherein the light is administered using a probe or catheter.
20 . The method of claim 19 , wherein the probe is an intra-pharyngeal probe.
21 . The method of claim 1 , wherein the light is administered using an implant.
22 . The method of claim 21 , wherein the implant lies between the skull and the scalp.
23 . The method of claim 1 , further comprising applying a magnetic field.
24 . The method of claim 1 , wherein the light is applied at a frequency in the range of alpha waves, beta waves, theta waves, or gamma waves.
25 . The method of claim 24 , wherein the light is applied at a frequency between 30 and 50 Hz.
26 . The method of claim 1 , further comprising administering pharmaceutical agents to the patient such that they pass through the blood brain barrier.
27 . The method of claim 26 , wherein the pharmaceutical agents are anticancer agents, and the method is used to treat brain cancer.
28 . The method of claim 27 , wherein the anticancer agents are selected from the group consisting of 5FC, Accutane, AEE788, AMG-102, Anti Neoplaston, AQ4N (Banoxantrone), AVANDIA (Rosiglitazone Maleate), Avastin (Bevacizumab) BCNU, BiCNU, Carmustine, Carboplatin, CC-223, CC223, CCI-779, CCNU, CCNU Lomustine, Celecoxib (Systemic), Chloroquine, Cilengitide (EMD 121974), Cisplatin, CPT-11 (CAMPTOSAR, Irinotecan), Cytoxan, Dasatinib (BMS-354825, Sprycel), Etoposide (Eposin, Etopophos, Vepesid), GDC-0449, Gleevec (imatinib mesylate), GLIADEL Wafer, Hydroxychloroquine, Hydroxyurea, IL-13, IMC-3G3, Iressa (ZD-1839), Lapatinib (GW572016), Methotrexate, Novocure, OSI-774, PCV, Procarbazine, RAD001, Rapamycin (Rapamune, Sirolimus), RMP-7, RTA 744, Simvastatin, Sirolimus, Sorafenib, SU-101, SU5416 Sugen, Sulfasalazine (Azulfidine), Sutent, Tamoxifen, TARCEVA (erlotinib HCI), Taxol, TEMODAR, TEMODAR, Thalomid (thalidomide), Toca 511, Topotecan (Systemic), VEGF Trap, VEGF-Trap, Velcade, Vincristine, Vorinostat (SAHA), XL 765, XL-184, XL184, XL765, Zarnestra (tipifarnib), and Zocor (simvastatin).
29 . The method of claim 27 , wherein the brain cancer is selected from the group consisting of gliomas, glioblastoma multiforme, meningiomas, ependymomas, pituitary tumors, craniopharyngiomas, germ cell tumors, pineal region tumors, medulloblastomas, and primary central nervous system (CNS) lymphomas.